STOCKS TELEGRAPH

Tag: LIXT Stock

  • Lixte Biotechnology Holdings Inc. (LIXT) Down After Hours on ATM Registered Direct Offering

    On April 12, Lixte Biotechnology Holdings Inc. (LIXT) came out with a couple of pieces of news that made the stock move up and down. The latest news from the company was a registered direct offering priced At-The-Market. This caused the stock to plunge down to $1.66 in the after-hours with a loss of 9.78%. This decline came after the stock’s rally of a humungous 67.27% in regular trading. The rally was a result of promising preclinical data from its lead program in KRAS-Mutant Cancers.

    Source: Bio Space

    LIXT’s ATM Offering

    The company has commenced a registered direct offering of 2,900,000 shares of its common stock at a price of $2.00 per share. Moreover, the offering is expected to generate gross proceeds of roughly $5.8 million for the company. LIXT plans to use the net proceeds from the offering for general corporate purposes as well as for the development of its lead clinical compound.

    With WestPark Capital Inc. and WallachBeth Capital LLC as co-placement agents, the offering is expected to close around April 14, 2022.

    Lead Cancer Candidate Data

    LB-100 is the company’s lead clinical cancer candidate which is currently under development.

    On Monday, Professor Rene Bernards, Netherlands Cancer Institute (NKI), Amsterdam, presented new data on LB-100 at the AACR Annual Meeting. The Annual Meeting of the American Association for Cancer Research (AACR) commenced on April 10 in New Orleans, LA, and will conclude on April 13, 2022. The presentation was a part of the celebratory events of Prof. Bernards’ selection as the awardee of the 2022 AACR Princess Takamatsu Memorial Lectureship.

    The new data suggest that LB-100 induces further activation of oncogenic signaling in various KRAS-mutant cancer. Thus, rendering the cancer cells vulnerable to anti-cancer therapy.

    Healthcare Stocks

    Despite the uncertainties in the market, healthcare stocks have had a record week. Amid the global volatility due to the Russia-Ukraine conflict, China-U.S. audit issues, and the increasing inflation and spiking interest rates, investors are placing safe bets. As always seen, the healthcare sector is one of the least impacted sectors by conflicts and crises. Thus investors have been flocking to healthcare stocks recently while the companies themselves also had a role to play.

    Therefore, the S&P 500 Healthcare has outperformed the market with a rise of 3.4% in recent days against a decline of 1.3% in the overall S&P 500.

    Conclusion

    After gaining a huge chunk during regular trading on Tuesday, LIXT fell down in the after-hours due to ATM offering. Given the huge gain, the stock was already posing for corrections soon, so, the news of the offering brought about the downfall before corrections could apply.

  • How Did The LIXT Stock Rise In Pre-Market Session?

    Lixte Biotechnology Holdings Inc. (LIXT) shares rose 13.76 percent to $3.39 in pre-market trade Thursday. The market price of Lixte stock ended last trading day at $2.96, down -6.92%. Trading volume for LIXT stock was 62899 shares, less than the average daily trading volume of 0.25 million shares over the past 50 days.

    While they have retreated -1.33% over the last five days, shares of LIXT have lost -1.00% in the past month. This year, LIXT has lost -48.88 percent so far and has lost -0.34% over the last three months. In response to outside research on its cancer treatment compound, LIXT stock rose.

    What research has been done?

    In addition to developing drugs for many types of cancer, Lixte Biotechnology is tackling more serious common diseases through research. One of the major causes of cancer is the malfunctioning of the switches that turn the biochemical pathways “on” and “off” in cells.

    During the past 30 years, cancer research has largely focused on “on” switches since “off” switches, especially the protein phosphatase (PP2A) master “off” switch, caused unacceptably high toxicities in patients. LB-100, LIXT’s novel, first-in-class lead compound, was found to be well tolerated in cancer patients at doses associated with anti-cancer activity, demonstrating that it has the potential to prevent the development of cancer.

    On Tuesday, Lixte announced that National Latino Leader Award winner Julio Pimentel from Wayne State University School of Medicine’s Cancer Biology program had been chosen for the second time to receive a scholarship and the award.

    • The Society of Advancing Chicanos/Hispanics and Native Americans in the Sciences Conference, taking place October 25-29, 2021, will be the perfect venue for Pimentel where he will present virtually studies of LB-100 in triple negative breast cancer (TNBC).
    • The award acknowledges his considerable achievements in research despite the challenges caused by COVID 19.
    • Pimentel and his coauthors were congratulated by LIXT for demonstrating that LB-100 inhibits TNBC cell growth, whether the cells are resistant to TRAIL or not.
    • LIXT’s LB-100 sensitizes TNBC cells to chemotherapy drugs like paclitaxel and cisplatin, which are used regularly for treating TNBC.
    • Researchers Pimentel and his colleagues concluded that inhibition of PP2A activity has therapeutic potential in treating this notoriously unresponsive type of breast cancer.

    The LB-100 strategy of LIXT:

    Many preclinical studies have shown that LB-100 can enhance conventional therapy for many types of cancer, including some of the most aggressive kinds. A good example of this is the report from Wayne State University. Lixte (LIXT) is evaluating LB-100 as a component of chemotherapy for TNBC, and is seeking a partner interested in conducting studies on LB-100 there.

  • Early Morning Vibes: Check These 4 Hot Stocks Right Now

    Early Morning Vibes: Check These 4 Hot Stocks Right Now

    Yesterday the US indices plunged deep into the red again. The last two days have seen a brave recovery, but panic broke out yesterday. The S&P 500 index lost 2.45% from a position of 3,829 points and the Nasdaq index fell 3.52% and closed at 13,119 points. The rising bond yields are now really starting to hurt investors. Ten-year yields rose to 1.49% on Thursday and the US 30-year Treasury bond even yields 2.28%. For the first time since early 2020, you will now receive a higher interest rate on this long-term bond than you will receive in dividends on stocks (S&P 500). 

    Technology stocks in particular seem to be affected by these higher interest rates. In recent days, the Nasdaq has lost more than the S&P and Dow Jones. Refinancing debt simply becomes more expensive and thus attracting new capital becomes more difficult. Hardest stocks are hit the hardest, because investors can still get out there with good profits. For example, Baidu lost 10% yesterday and Tesla again lost more than 10%. NVIDIA fell 7.11% and Spotify lost a whopping 9.45%.

     Positive outliers were Twitter (+ 3.71%) and GameStop (+ 18.56%). Twitter revised its earnings forecast upwards and GameStop responded positively to the CFO replacement.
     Today, the sell-off seems to be taking another tail, as futures are sharply lower. In the US, the Nasdaq Future is already 0.7% in the red. 

    Meanwhile, it is hoped that the interest rate rise will cool down quickly, because we are currently seeing panic across the entire market. The VIX (Volatility Index) has risen to a level of 28 points and even gold and silver are being hit. People really seem to be looking for liquidity, because even Bitcoin (-8%) is significantly lower today.

    Today Top Movers

    Lixte Biotechnology Holdings Inc (LIXT)is up 29.97% to $4.90 in premarket trading today.

    Armstrong Flooring Inc. (AFI) stock soared 36.14% to $5.5 in the pre-market trading after signing a definitive agreement to sell South Gate, California property for $76.7 million.

    Northern Dynasty Minerals Ltd. (AMEX: NAK) shares are trading up 33.14% at $0.932 at the time of writing.

    Sensus Healthcare Inc. (SRTS) grew over 15.18% at $4.4 in pre-market trading today. The company recently declared fourth quarter and full year 2020 financial results.

    Top Upgrades & Downgrades

    Needham turned bullish on LivePerson Inc. (LPSN), upgrading the stock to “Buy” and assigning a $71.0 price target, representing a potential upside of 35.81% from Thursday’s close. 

    NetApp Inc. (NTAP) has won the favor of Daiwa’s equity research team. The firm upgraded the shares from Neutral to Outperform and moved their price target to $70, suggesting a 14.36% additional upside for the stock. 

    Spirit Realty Capital Inc. (SRC) received an upgrade from analysts at UBS. They changed their rating on SRC to Neutral from Sell in a recently issued research note.

    Earlier Friday Baird reduced its rating on Voyager Therapeutics Inc. (VYGR) stock to Neutral from Outperform and assigned the price target to $6. 

    Raymond James analysts reduced their investment ratings, saying in research reports covered by the media that it’s rating for Best Buy Co. Inc. (BBY) has been changed to Outperform from Strong Buy and the new price target is set at $120. 

    Analysts at SVB Leerink downgraded Pandion Therapeutics Inc. (PAND)’s stock to Market Perform from Outperform Friday.

    Latest Insider Activity

    PayPal Holdings Inc. (PYPL) EVP, Chief Strategy & Growth Auerbach Jonathan announced the sale of shares taking place on Feb 23 at $261.38 for some 46,134 shares. The total came to more than $12.06 million. 

    Tapestry Inc. (TPR) VP, Controller, and PAO Dadlani Manesh sold on Feb 24 a total of 19,753 shares at $41.47 on average. The insider’s sale generated proceeds of almost $6801. 

    Ford Motor Company (F) Director THORNTON JOHN L declared the purchase of shares taking place on Feb 23 at $11.62 for some 8,620 shares. The transaction amount was around $0.1 million. 

    DuPont de Nemours Inc. (DD) Director CURTIN TERRENCE R bought on Feb 22 a total 7,500 shares at $69.94 on average. The purchase cost the insider an estimated $524,549.

    Important Earnings

    Top US earnings releases scheduled for today include DraftKings Inc. (NASDAQ: DKNG). It will announce its Dec 2020 financial results. The company is expected to report earnings of -$0.47 per share from revenues of $232.6M in the three-month period. 

    Analysts expect Vistra Corp. (NYSE: VST) to report a net income (adjusted) of $0.76 per share when the company releases its quarterly results shortly. Revenue for the fiscal quarter ended Dec 2020 is predicted to come in at $3.39B. 

    EOG Resources Inc. (EOG), due to announce earnings before the market opens today, is expected to report earnings of $0.8 per share from revenues of $3.04B recently concluded three-month period.